(Q34504825)

2 August 2017

title

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro (English)

1 reference

2 August 2017

1 reference

1 reference

1 reference

Jan Paeshuyse

1

0 references

Ralf Bartenschlager

Ralf Bartenschlager

7

0 references

Erik De Clercq

Erik De Clercq

3

0 references

Johan Neyts

Johan Neyts

8

0 references

Jean-Maurice Dumont

5

Jean-Maurice Dumont

1 reference

2 August 2017

6

Pietro Scalfaro

1 reference

2 August 2017

4

Brigitte Rosenwirth

1 reference

2 August 2017

Artur Kaul

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

2 August 2017

1 reference

2 August 2017

volume

43

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

761-770

1 reference

The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells

2 August 2017

cites work

1 reference

Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog

21 January 2018

1 reference

Novel insights into hepatitis C virus replication and persistence

21 January 2018

1 reference

7 January 2021

Clinical consequences of hepatitis C virus infection.

1 reference

7 January 2021

Clinical trial results of peginterferons in combination with ribavirin

1 reference

7 January 2021

Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation

1 reference

7 January 2021

Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells

1 reference

7 January 2021

Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity

1 reference

7 January 2021

Schistosoma japonicum is less sensitive to cyclosporin A in vivo than Schistosoma mansoni.

1 reference

7 January 2021

Synergistic action of cyclosporin A and polyspecific rabbit anti-sera against murine Schistosoma mansoni

1 reference

7 January 2021

The larvicidal activity of cyclosporin A against Schistosoma mansoni in mice.

1 reference

7 January 2021

Suppressive effects of cyclosporin A in murine schistosomiasis

1 reference

7 January 2021

Protection against schistosomiasis produced by cyclosporin A

1 reference

7 January 2021

Antischistosomal effects of cyclosporin A

1 reference

7 January 2021

Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin

1 reference

7 January 2021

Plasmodium vivax: in vitro antiparasitic effect of cyclosporins

1 reference

7 January 2021

Specific inhibition of hepatitis C virus replication by cyclosporin A.

1 reference

7 January 2021

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes

1 reference

7 January 2021

A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients

1 reference

7 January 2021

Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease

1 reference

7 January 2021

Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial

1 reference

7 January 2021

Synthetic routes to NEtXaa4-cyclosporin A derivatives as potential anti-HIV I drugs

1 reference

7 January 2021

Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs

1 reference

7 January 2021

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

1 reference

7 January 2021

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

1 reference

7 January 2021

A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C.

1 reference

7 January 2021

Mutations in Hepatitis C Virus RNAs Conferring Cell Culture Adaptation

1 reference

7 January 2021

Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication

1 reference

7 January 2021

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

1 reference

7 January 2021

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

1 reference

7 January 2021

Complete replication of hepatitis C virus in cell culture

1 reference

7 January 2021

Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations

1 reference

7 January 2021

A three-dimensional model to analyze drug-drug interactions

1 reference

7 January 2021

Robust hepatitis C virus infection in vitro

1 reference

7 January 2021

Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins

1 reference

7 January 2021

Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21102

1 reference

2 August 2017

1 reference